Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2005-07-14
2008-09-16
Kemmerer, Elizabeth C. (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C435S069100, C435S069700, C435S252300, C435S254200, C435S348000, C435S349000, C435S366000
Reexamination Certificate
active
07425614
ABSTRACT:
Methods for identifying neuroprotective compounds, as well as compositions and methods for treating subjects suffering from neurological diseases or disorders are provided.
REFERENCES:
patent: 5656595 (1997-08-01), Schweighoffer et al.
patent: 6319955 (2001-11-01), Alessandrini et al.
patent: 6413942 (2002-07-01), Felgner et al.
patent: 6451837 (2002-09-01), Baskys
Krapivinsky et al. 2003. Neuron. 40: 775-784.
Phillips, A., J Pharm Pharmacology 53: 1169-1174, 2001.
Luo et al, 1997. Molecular Pharmacology. 51: 79-86.
Shou et al, 1992. Nature. 358(6384): 351-4.
Wells (Sep. 18, 1990) “Additivity of Mutational Effects in Proteins.” Biochemistry 29(37): 8509-8517.
Ngo et al. (Mar. 2, 1995) “The Protein Folding Problem and Tertiary Structure Prediction, Chapter 14: Computational Complexity Protein Prediction, and the Levinthal Paradox” pp. 492-495.
Bork (2000) “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle.” Genome Research 10:398-400.
Skolnick and Fetrow (2000) “From gene to protein structure and function: novel applications of computational approaches in the genomic era.” Trends in Biotech. 18(1): 34-39.
Doercks et al. (Jun. 1998) “Protein annotation: detective work for function prediction.” Trends in Genetics 14(6): 248-250.
Smith and Zhang (Nov. 1997) “The challenges of genome sequence annotation or ‘The devil is in the details’.” Nature Biotechnology 15:1222-1223.
Brenner (Apr. 1999) “Errors in genome annotation.” Trends in Genetics 15(4): 132-133.
Bork and Bairoch (Oct. 1996) “Go hunting in sequence databases but watch out for the traps.” Trends in Genetics 12(10): 425-427.
Hess et al, 1996. J Pharmacol Exp Ther. 278(2): 808-816.
Abel, T. and Lattal, K.M., “Molecular Mechanisms of Memory Acquisition, Consolidation and Retrieval,”Current Opinion in Neurobiology, 11:180-187 (2001).
Bayer et al., “Interaction with NMDA Receptor Locks CaMKll in an Active Conformation,” Nature, 411:801-805 (2001).
Becq et al., “Anatomical and Functional Reconstruction of the Nigrostiatal System In Vitro: Selective Innervation of the Striatum by Dopaminergic Neurons,” Journal of Neuroscience Research, 58:553-566 (1999).
Bonni et al., “Cell Survival Promoted by the Ras-MAPK Signaling Pathway by Transcription-Dependent and -Independent Mechanisms,” Science, 286:1358-1362 (1999).
Brewer, G.J., “Serum-Free B27/Neurobasal Medium Supports Differentiated Growth of Neurons From the Striatum, Substantia Nigra, Septum, Cerebral Cortex, Cerebellum, and Dentate Gyrus,” Journal of Neuroscience Research, 42:674-683 (1995).
Chatterton et al., Excitatory gllycine receptors conatining the NR3 family NMDA receptor subunits, Nature, 415:793-798 (2002).
Cull-Candy et al., “NMDA Receptor Subunits: Diversity, Development and Disease,” Current Opinion in Neurobiology, 11:327-335 (2001).
Das et al., “Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A,” Nature, 393:377-381 (1998).
Dolmetsch et al., “Signaling to the Nucleus by an L-type Clacium Channel- Calmodulin Complex Through the MAP Kinase Pathway,” Science, 294:333-339 (2001).
Farnsworth et al., “Calcium Activation of Ras Mediated by Neuronal Exchange Factor Ras-GRF,” Nature, 376(6540):524-527 (1995).
GenBank Accession No. AAD00659 “N-methyl-D-aspartate receptor subunit 2B [Homo sapiens],” (Jan. 5, 1999).
GenBank Accession No. CAA47666, “P140 RAS-GRF [Rattus rattus],” (Apr. 18, 2005).
GenBank Accession No. NM—002891, “Homo sapiensRas protein-specific guanine nucleotide-releasing factor 1 (RASGRF1), transcript variant 1, mRNA,” Jun. 30, 2007).
GenBank Accession No. NP—002882, “Ras protein-specific guanine nucleotide-releasing factor 1 isoform 1 [Homo sapiens]” (Jun. 30, 2007).
GenBank Accession No. NM—012574, “Rattus norvegicusglutamate receptor, ionotropic, N-methyl D-aspartate 2B (Grin2b), mRNA” (Jul. 30, 2007).
GenBank Accession No. NP—036706, “glutamate receptor, ionotropic, N-methyl D-aspartate 2B [Rattus norvegicus]” (Jul. 30, 2007).
GenBank Accession No. NP—722522, “Ras protein-specific guanine nucleotide-releasing factor 1 isoform 2 [Homo sapiens]” (Jun. 30, 2007).
GenBank Accession No. U88963, “Human N-methyl-D-aspartate receptor subunit 2B (GRIN2B) mRNA, complete cds” (Jan. 5, 1999).
GenBank Accession No. X67241, “R. rattusmRNA for guanine nucelotide releasing factor for RAS P21” (Apr. 18, 2005).
Ghosh, A. and Greenberg, M., “Calcium Signaling in Neurons: Molecular Mechanisms and Cellular Consequences,” Science, 268:239-247 (1995).
Gill et al., “Pharmacological Characterization of Ro 63-1908 (1-[2-(4-Hodroxy-phenoxy)-ethyl]-4-(4-methyl benzyl)-piperidin-4-ol), a Novel Subtype-Selective N-Methyl-D-Aspartate Antagonist,” J. Pharmacol. Exp. Ther., 302(3):940-948 (2002).
Ginty, D. et al., “Regulation of CREB Phosphorylation in the Suprachiasmatic Nucleus by Light and a Circadian Clock,” Science, 260:238-241 (1993).
Hoffman H. et al., “Synaptic Activity-Dependent Developmental Regulation of NMDA Receptor Subunit Expression in Cultured Neocortical Neurons,” Journal of Neurochemistry, 75(4):1590-1599 (2000).
Ikonomidou et al., “Blockade of NMDA Receptors and Apoptotic Neurodegeneration in Developing Brain,” Science, 283:70-74 (1999).
Kemp et al., “NMDA Receptor Antagonists and Their Potential as Neuroprotective Agents,” Handbook of Experimental Pharmacology, (eds. Jonas, P. & Monyer, H., Springer, Berlin) 141:495-527 (1999).
Kemp, J. and McKernan, R., “NMDA receptor pathways as drug targets,” Nature Neuroscience Supplement, 5:1039-1042 (2002).
Le, D. and Lipton, S., “Potential and Current Use of N-Methyl-D-Apartate (NMDA) Receptor Antagonists in Diseases of Aging,” Drugs and Aging, 18(10):717-724 (2001).
Lees et al., “Glycine anatagonists (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial,” The Lancet, 355:1949-1954 (2000).
Li et al., “Developmental Changes in Localization of NMDA Receptor Subunits in Primary Cultures of Cortical Neurons,” European Journal of Neuroscience, 10:1704-1715 (1998).
Martegani et al., “Cloning by functional complementation of a mouse cDNA encoding a homologue of CDC25, aSaccharomyces cerevisiaeRAS activator,” The EMBO Journal, 11(6):2151-2157 (1992).
Medina et al., “Mobilization of intracellular calcium stores participates in the rise of [Ca2+]i and the toxic actions of the HIV coat protein GP120,” European Journal of Neuroscience, 11:1167-1178 (1999).
Monyer et al., “Developmental and Regional Expression in the Rat Brain and Functional Properties of Four NMDA Receptors,” Neuron, 12:529-540 (1994).
Nash, J. and Brotchie, J., “Characterisation of Striatal NMDA Receptors Involved in the Generation of Parkinsonisan Symptoms: Intrastriatal Microinjection Studies in the 6-OHDA-Lesioned Rat,” Movement Disorders, 17(3):455-466 (2002).
Payne et al., “Identification of the Regulatory Phosphorylation Sites in pp42/Mitogen-Activated Protein Kinase (MAP Kinase),” The EMBO Journal, 10(4):885-892 (1991).
Platenik et al., “Molecular Mechanisms Associated with Long-Term Consolidation of the NMDA Signals,” Life Sciences, 67:335-364 (2000).
Sacco et al., “Glycine Antagonist in Neuroprotection for Patients With Acute Stroke,” JAMA, 285(13):1719-1728 (2001).
Sheng et al., “Changing Subunit Composition of Heteromeric NMDA Receptors During Development of Rat Cortex,” Nature, 368:144-147 (1994).
Stoppini et al., “A simple method for organotypic cultures of nervous tissue,” Journal
Clapham David
Krapivinsky Grigory
Medina Igor
Yehezkel Ben-Ari
Children's Medical Center Corporation
Foley & Hoag LLP
Howard Zachary C
Institut National de la Sante et de la Recherche Medical (INSERM
Kemmerer Elizabeth C.
LandOfFree
Neuroprotective therapeutics preventing ERK/MAPK activation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neuroprotective therapeutics preventing ERK/MAPK activation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neuroprotective therapeutics preventing ERK/MAPK activation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3982492